Illumina's margin expansion and a coming revenue recovery should help the stock multiples re-rate toward life science ...

In addition, recent advancements for its MiSeq i100 Series sequencing instrument have helped Illumina strengthen its foothold ...

SAN DIEGO, Oct. 24, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today unveiled its MiSeq™ i100 Series of sequencing ...

Customers will also share data from studies using the technologies including an effort to investigate protein biomarkers for ...

Illumina, a United States-headquartered company specializing in DNA sequencing and array-based technologies, is showcasing ...

While Illumina maintains a strong position in the sequencing market, the company faces increasing competitive pressures. The introduction of new products, such as the MiSeq i100 series ...

Illumina’s strategic initiatives include the launch of the MiSeq i100 Series, a new benchtop sequencer aimed at accelerating genomic innovation. The company has also announced plans to expand its ...

Designed to make next-generation sequencing accessible to more labs SAN DIEGO, Oct. 24, 2024 /PRNewswire/ -- Illumina, Inc.

While Illumina maintains a strong position in the sequencing market, the company faces increasing competitive pressures. The introduction of new products, such as the MiSeq i100 series, is seen as a ...